NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 05/05/2022 10:34
Last Report Issued 03/17/2022 08:07

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 4783B
Patient ID 4783B
Chain 22000663
DOB Not Given
Sex Not Given
Workorder 22000663
Received 02/14/2022

Lab ID 22000663-001
Matrix Blood
Patient Name 4783B
Patient ID 4783B
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
4783B Voclosporin, Blood				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Voclosporin	None Detected	ng/mL	1.0	
Synonym(s): Lupkynis®				
Voclosporin is a calcineurin inhibitor approved for the treatment of adults with lupus nephritis. Published Phase 3 clinical trial data indicated voclosporin in combination with mycophenolate mofetil (MMF) and low-dose steroids led to a clinically and statistically superior complete renal response rate versus MMF and low-dose steroids alone, with a comparable safety profile. Peak whole blood concentrations are reported to average 32 +/- 9.9 ng/mL and 950 +/- 250 ng/mL approximately 1-2 hours following single oral doses of voclosporin at 0.25 mg/kg and 4.5 mg/kg, respectively.				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.